PTAB Update: Wins, Losses and Appeals

April 24, 2018 9:00am

Dominick A. Conde
Fitzpatrick, Cella, Harper & Scinto (New York, NY)

Stephen M. Hash
Baker Botts LLP (Austin, TX)

Joseph A. Hynds
Rothwell, Figg, Ernst & Manbeck, P.C. (Washington, DC)

Laura A. Lydigsen
Brinks Gilson & Lione (Chicago, IL)

Lars Taavola
Senior Director / Senior Patent Counsel - Global Intellectual Property, Head of Patent Litigation
Amneal Pharmaceuticals LLC (Bridgewater, NJ)

Dennies Varughese
Sterne, Kessler, Goldstein & Fox P.L.L.C. (Washington, DC)


Honorable Teresa Rea
Crowell & Moring LLP (Washington, DC) (Former Acting Under Secretary of Commerce for Intellectual Property and Former Acting Director of the United States Patent and Trademark Office)

  • Survey of notable pharmaceutical patent wins and losses
  • Overview of IPR, PGR and CBM filings involving pharmaceutical patents
  • Examining the latest statistics for types of challenges brought and types of patents challenged
  • Investigating the Aqua Products decision
  • Understanding the Final Rule establishing patent agent privilege and its impact
  • Examining when the PTAB will issue a “good cause” extension of trial
  • Considering emerging case law shaping the role of prior art in the PTAB’s discretionary denial of inter partes review
  • Evaluating when petitioners may rely on prior art previously considered by the PTAB
  • Update on activity of reverse patent trolls
  • Status of pending patent reform legislation and its possible impact on the PTAB